Premium
Pityriasis rubra pilaris‐like erythroderma secondary to phosphoinositide 3‐kinase inhibition
Author(s) -
Dewan A. K.,
Sowerby L.,
Jadeja S.,
Lian C.,
Wen P.,
Brown J. R.,
Fisher D. C.,
LeBoeuf N. R.
Publication year - 2018
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.13608
Subject(s) - pityriasis rubra pilaris , medicine , erythroderma , dermatology , discontinuation , adverse effect , toxic epidermal necrolysis , skin cancer , drug eruption , malignancy , cancer , drug , pharmacology , psoriasis
Summary Background Phosphoinositide 3‐kinase (PI3K) inhibitors are a class of small‐molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described. Aim To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. Methods This was a retrospective analysis of patients receiving PI3K inhibitors referred to the Skin Toxicities Program in The Center for Cutaneous Oncology. Results Three patients on PI3K inhibitors for treatment of malignancy developed diffuse erythroderma and keratoderma. Clinical and histopathological findings were consistent with pityriasis rubra pilaris (PRP)‐like reactions. All patients improved with topical and oral corticosteroids, oral acitretin, and drug discontinuation. Conclusions PRP‐like cutaneous eruptions may develop secondary to PI3K inhibition. Early dermatological evaluation of cutaneous toxicities to PI3K inhibitors as well as rapid initiation of disease‐specific treatments may help keep patients on life‐prolonging anti‐cancer therapies.